Page 1084 - Clinical Immunology_ Principles and Practice ( PDFDrive )

ChaPTEr 77 Immunotherapy of Cancer 1048.e1

MULT i PLE-C h O i CE QUEST i ONS

1. The immunotherapy regimen associated with the “maximum A. Programmed death 1 (PD-1)/PD-L1
response” or the most patients with significant reduction in B. PD-L1/CD80
tumor burden based on phase III clinical trials completed to C. Inducible T-cell costimulator (ICOS)/ICOS-L
date is ———? D. CD68/cytotoxic T lymphocyte antigen-4 (CTLA-4)
A. Nivolumab 3. A 28-year-old female is diagnosed with cutaneous melanoma
B. Ipilimumab on her right shoulder. After surgical resection and imaging,
C. Nivolumab plus ipilimumab she is diagnosed with stage III melanoma. She is interested
D. Pembrolizumab
in receiving adjuvant immune checkpoint therapy to reduce
2. A 64-year-old patient was diagnosed with a large 11.5-cm the risk of relapse at 3 years. Which immune checkpoint
mass in the left kidney. The patient underwent nephrectomy, inhibitor has received US Food and Drug Administration
which revealed a pT3aN0cM0 clear-cell renal cell carcinoma. (FDA) approval for this indication?
After 2 years of observation, he was found to have numerous A. Nivolumab
pulmonary metastases. He was treated with sunitinib (Sutent) B. Ipilimumab
for 15 months and was later found to have disease progression. C. Atezolizumab
His physician is interested in treating him with nivolumab. D. Pembrolizumab
Which pathway does nivolumab target?